SAB Biotherapeutics, Inc. cotiza a 2.68 USD y tiene una capitalización bursátil de $244M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunot…
| Periodo | 2026-11 | 2026-08 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | — | $-0.28 | $-0.41 | $0.50 |
| Estimado | $-0.27 | $-0.28 | $-0.17 | $-0.46 |
| Sorpresa | — | +0.0% | -141.2% | +208.7% |
| Métrica | SABS | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | 8.8% | -40.4% | +49.2% |
| ROA | 7.7% | -32.0% | +39.7% |
| Current Ratio | 9.46 | 2.84 | +6.62 |
| Debt / Equity | — | 0.28 | — |